Recent Updates — ACRS
Aclaris Therapeutics entered into an underwriting agreement to sell 7,785,714 shares of common stock and pre-funded warrants for 6,500,000 additional shares. The offering price is set at $3.50 per share of common stock and $3.49999 per pre-funded warrant. Net proceeds are estimated at approximately $46.7 million after deducting underwriting discounts and expenses. Closing is expected on October 28, 2026. The company operates in the biopharmaceutical industry.
Aclaris Therapeutics announced primary analysis results from Phase 1b proof-of-concept trials of its anti-TSLP/IL-4Rα bispecific antibody ATI-052. In severe atopic dermatitis, patients treated with ATI-052 experienced a 45% placebo-adjusted mean improvement in EASI scores and a 43% placebo-adjusted reduction in itch (PP-NRS) by day 57. In asthma, a single dose of ATI-052 resulted in a 59% mean reduction in fractional exhaled nitric oxide (FeNO) at day 15 and a 200 mL improvement in FEV1 compared to placebo. The compound demonstrated a favorable safety profile with no conjunctivitis observed. Aclaris intends to prioritize Phase 2b development of ATI-052 in eosinophilic esophagitis (EoE) starting early next year. Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing novel product candidates for immuno-inflammatory diseases.
Aclaris Therapeutics entered into a Second Amended and Restated Sales Agreement with Leerink Partners LLC and Cantor Fitzgerald to offer and sell shares of common stock through at-the-market offerings. This agreement amends the previous facility dated February 27, 2025, which had a $100.0 million limit. The new arrangement allows sales at the Company's sole discretion based on market conditions and instructions regarding price or size limits. The Company will pay a commission of 3.0% of gross sales proceeds to the agents. Aclaris Therapeutics operates in the biopharmaceutical industry, developing treatments for inflammatory diseases.
Aclaris Therapeutics reported second quarter and six-month financial results for the period ended June 30, 2026. The company posted a net loss of $21.5 million ($0.15 per share) for the quarter and $41.3 million ($0.30 per share) year-to-date, compared to prior year losses of $15.4 million and $30.5 million respectively. Total revenue was $1.6 million for the quarter and $3.6 million for the six-month period, driven by royalties from license agreements with Lilly and Sun Pharma. Research and development expenses increased to $18.1 million for the quarter due to costs associated with ATI-052 and ATI-9494. As of June 30, 2026, cash and marketable securities totaled $170.6 million. Subsequent to quarter-end, Aclaris sold 7.3 million shares under its ATM agreement for $40.2 million in gross proceeds. The company reaffirmed timelines for Phase 1b results of ATI-052, a Phase 2 readout for bosakitug, and the initiation of Phase 2b trials for ATI-052 and modzatinib in late 2026. Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing novel product candidates for immuno-inflammatory diseases.